Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Int J Biol Markers ; 9(1): 48-52, 1994.
Article in English | MEDLINE | ID: mdl-8051435

ABSTRACT

The use of tumor marker tests has increased progressively in the last decade concomitant with the advent of new monoclonal antibodies and their growing use in clinical oncology for various follow-up programs. External quality assessment (EQA) schemes widely adopted in clinical chemistry, have been extended in the last decade to immunoassays of hormones and tumor markers. EQA results can provide realistic information on the quality of the assays, performed under routine conditions. The goal of this article is to report the main results and discrepancies encountered so far in External Quality Assessment programs on tumor markers.


Subject(s)
Biomarkers, Tumor/analysis , Immunoassay/standards , Neoplasms/blood , Analysis of Variance , Biomarkers, Tumor/blood , Evaluation Studies as Topic , Female , Humans , Immunoassay/methods , Italy , Laboratories , Male , Quality Control
2.
Am J Obstet Gynecol ; 168(1 Pt 1): 71-8, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8420353

ABSTRACT

OBJECTIVE: The aim of the study was to investigate the biologic significance of p21 expression in normal and neoplastic ovarian tissues. STUDY DESIGN: Western blotting analysis of p21/ras oncoprotein was conducted in a group of 14 normal and cystic ovaries, six benign tumors, 42 primary ovarian cancers, and 15 omental metastases. RESULTS: Levels of p21 were similar in normal and cystic ovaries and in benign tumors, whereas they were significantly higher in malignant tumors than in control tissues (median 1.91, range 0.12 to 5.00 vs median 1.03, range 0.32 to 2.20; p = 0.023) and in omental metastases than in primary ovarian carcinomas (median 3.05, range 0.55 to 5.72 vs median 1.97, range 0.12 to 5.00; p = 0.14). We found no correlation between p21 expression and histopathologic or clinical characteristics. Estrogen receptor-positive and progesterone receptor-positive tumors expressed higher p21 levels than did estrogen receptor-negative and progesterone receptor-negative tumors (p < 0.05), but no correlation with epidermal growth factor receptor status was found. In the univariate analysis of survival p21 positivity showed a negative prognostic value. CONCLUSION: The enhancement of p21 protein is associated in the ovarian tissue with the malignant phenotype and the acquisition of metastatic potential.


Subject(s)
Omentum , Oncogene Protein p21(ras)/analysis , Ovarian Cysts/chemistry , Ovarian Neoplasms/chemistry , Ovary/chemistry , Peritoneal Neoplasms/chemistry , Peritoneal Neoplasms/secondary , Adult , Aged , Blotting, Western , ErbB Receptors/analysis , Female , Humans , Middle Aged , Neoplasm Staging , Ovarian Cysts/mortality , Ovarian Cysts/pathology , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Ovary/pathology , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...